АКЦИОНЕРНОЕ ОБЩЕСТВО КЛИНИЧЕСКИЙ ГОСПИТАЛЬ «НЕЙРОВИТА»
  • Адрес электронной почты защищен от спам-ботов. Для просмотра адреса в вашем браузере должен быть включен Javascript.
  • 8 (495) 147-49-49
  • Проконсультироваться со специалистом

    Обратная связь

    Ваше сообщение было успешно отправлено

  • 8 (903) 737 48 97
  • Технологии лечения

    Технологии лечения

THE DOCTORS OF NEUROVITA CLINICAL HOSPITAL

In our Hospital you can receive the consultations and services of experienced and highly qualified specialists in the fields of oncology, neurology and neurosurgery who have been trained both in Russia and abroad.

Bryukhovetsky Andrey Stepanovich

Bryukhovetsky
Andrey Stepanovich

General Director, Professor,
Doctor of Medical Sciences

More

Ustyugov Andrey Yurievich

Ustyugov
Andrey Yurievich

Chief Physician, Associate Professor, Candidate of Medical Sciences.

More

Kovalenko Nikolay Ivanovich

Kovalenko Nikolay Ivanovich

Doctor neurologist of the highest category, head of the hospital

More

Zhilyaev Andrey Gennadievich

Zhilyaev
Andrey Gennadievich

Медицинский психолог, врач психотерапевт, доктор медицинских наук, профессор.

More

Falaleeva Natalya Alexandrovna

Falaleeva Natalya Alexandrovna

Doctor of Medical Sciences,
oncologist-chemotherapist

More

Nekrasova Anastasia Viktorovna

Nekrasova Anastasia Viktorovna

Candidate of Medical Sciences,
oncologist-hematologist

More

Suleymanova Zuleikha Abakarovna

Suleymanova Zuleikha Abakarovna

Candidate of Medical Sciences, doctor of the highest category, obstetrician-gynecologist

More

Alekseev Vladimir Alexandrovich

Alekseev
Vladimir Alexandrovich

Кандидат медицинских наук,
врач онколог-хирург

More

Yurichev Ilya Nikolaevich

Yurichev
Ilya Nikolaevich

Candidate of Medical Sciences,
endoscopist

More

Rimskaya Elena Mikhailovna

Rimskaya
Elena Mikhailovna

Cardiologist-arrhythmologist, candidate of medical sciences

More

Chekalova Marina Albertovna

Chekalova
Marina Albertovna

Professor, MD,
Doctor of Ultrasound Diagnostics

More

Orokhovskaya Elena Valentinovna

Orokhovskaya Elena Valentinovna

Candidate of Medical Sciences, cardiologist, rheumatologist

More

Borunova Anna Anatolyevna

Borunova
Anna Anatolyevna

Candidate of Medical Sciences, allergist - immunologist

More

Volkov Alexey Nikolaevich

Volkov
Alexey Nikolaevich

Doctor anesthesiologist-resuscitator

More

Makarov Dmitry Igorevich

Makarov Dmitry Igorevich

Doctor
anesthesiologist-resuscitator

More

Teleshchuk Pavel Leonidovich

Teleshchuk
Pavel Leonidovich

Doctor
anesthesiologist-resuscitator

More

Khakimzyanova Milyausha Abuzarovna

Khakimzyanova Milyausha Abuzarovna

Doctor
anesthesiologist-resuscitator

More

Livanov Alexander Vladimirovich

Livanov Alexander Vladimirovich

Doctor
anesthesiologist-resuscitator

More

Dolgopolov Igor Stanislavovich

Dolgopolov
Igor Stanislavovich

Professor, doctor of medical sciences, oncologist of the highest category.

More

Tsurko Vladimir Viktorovich

Tsurko
Vladimir Viktorovich

Doctor of Medical Sciences, Professor, Consultant Rheumatologist and Therapist

More

Grivtsova Lyudmila Yurievna

Grivtsova
Lyudmila Yurievna

Candidate of Medical Sciences, Doctor of Biological Sciences, Head of Clinical Laboratory

More

Bragina Alena Dmitrievna

Bragina
Alena Dmitrievna

Pharmacist,
head of pharmacy

More

Popescu Dmitry Ivanovich

Popescu Dmitry Ivanovich

Rehabilitation team leader

More

Matsenko Ekaterina Sergeevna

Matsenko Ekaterina Sergeevna

Laboratory assistant

More

Zaripova Nelly Akhmetovna

Zaripova
Nelly Akhmetovna

X-ray technologist

Clinical Hospital «NEUROVITA»

The clinical basis of the Hospital used to be located in the facilities of the Federal State Budgetary Institution Blokhin NN National Medical Center of Oncology (NMCO), 23, Kashirskoye shosse, Moscow for over 20 years. Currently, the Hospital moved to a newly repaired specialized medical building with an address at Ul. Marshala Timoshenko 7, building 1, Moscow.

ogospitale

ogospitale2

A new facility of the Hospital is adjusted to the needs of tetraplegics and paraplegics and is suited for specific highly technological medical assistance to various types of the patients in the severe conditions. The Hospital offers well-equipped private and semi-private wards for patients. The rooms are air-conditioned, equipped with refrigerators and TV sets, medical gases supply as well as all with all appropriate devices for paraplegics and tetraplegics.

The Hospital has Intensive Care Units that are equipped for the therapy of the patients in grave conditions: artificial lung ventilation apparatuses, anesthetic apparatuses, infusion pumps and others. The Hospital is equipped with radiologic imaging equipment, neurophysiological testing equipment, such as EEG mapping, electroneuromyography, transcranial magnetic stimulation, as well as equipment for functional diagnostics, endoscopy, transfusiology, microneurosurgery, harvest of the mononuclear cells of the peripheral blood, laboratories, physiotherapy and a specialized gym.

The Chief Executive Officer of the Hospital, Professor Andrey S. Bryukhovetskiy, PhD, MD, the Doctor of Medical Sciences (according to the Russian ranking system), the neurologist of the top category, has been the head of the NeuroVita Clinic since the day of its foundation. The professor has been developing personalized therapy with the involvement of the technologies of regenerative and post-genomic medicine since 1996.

Being a Head Neurologist of the Russian Navy and the colonel of the Medical Military Service, Andrey Bryukhovetskiy led the programs of the Ministry of Defense on the treatment of the combat injury of the brain, was a member of the Expert Board of the Ministry of Health and Social Development on the cell technologies from 1998 till 2003, the coordinator of the branch program of the Russian Academy of Medical Science New Cell Technologies to Medicine  and currently is a vice president of the International Association of Neurorestoratology that united the leading experts in the stem cells. Andrey S. Bryukhovetskiy is an author of 210 publications in peer reviewed journals,15monographs, 22 patents for inventions of the Russian Federation and one USA patent. 

George L. Mentkevich, PhD, MD, the Doctor of Medical Sciences (according to the Russian ranking system), the oncologist and hematologist of the top category is the Chief Medical Officer of the Hospital and our leading expert in oncology for the past two years. Prof. Mentkevich took training courses in the leading US cancer centers and acquired a unique 30 years’ experience in the bone marrow and hematopoietic stem cells transplantation. George Mentkevich started his career in Blokhin NN NMCO as a clinical oncologist and hematologist and became the deputy chief officer of the Research Institute of Children Oncology and Hematology there. He is the author of over 200 articles and 5 monographs. 

The Hospital has a stable and closely connected team of the best specialists, the consultants, the doctors and the nurses, as well as management and administration. The Hospital regularly cooperates with five professors and doctors of medical sciences, five MDs, consults with ten professors and doctors of medical and biological sciences of Moscow, Saint Petersburg, Novosibirsk and Vladivostok. The Hospital has been multiply awarded with the diplomas of the Moscow Fund of the Protection of Consumers’ Rights. Back in 2010 the journal Paraplegia News considered the technologies of the Hospital to be the most promising to increase the efficacy of rehabilitation in spinal cord injury.

Our regular consultants are Prof. Nina A.Gorbunova, the doctor of medical sciences  (Moscow) for oncology and chemotherapy, Prof. Viktor I. Seledtsov, the doctor of medical sciences (Moscow)  for immunology, Prof. Elena R. Chernykh, the doctor of medical sciences (Novosibirsk) and Anna A. Borunova, MD (Moscow) for oncoimmunology; Prof. Valeriy E. Shevchenko, the doctor of biological sciences (Moscow) for oncoproteomics; Sergey S. Bogachov, the doctor of biological sciences (Novosibirsk) for genetics; Nikolay Yu. Mironov, MD for cardiology, Prof. Vladimir V. Tsurko, the doctor of medical sciences, for therapy and rheumatology, and many other specialists.

The Hospital is licensed for out-patient and in-patient medical care in neurology, neurosurgery, oncology, allergology and immunology, intensive care and anesthesiology, transfusiology, endoscopy, surgery, therapy, gastroenterology, radiology, laboratory diagnostics, physical training, massage, rehabilitation and nursing care.

The Hospital is licensed for the pharmaceutical practice including

  • circulation of medicines,
  • use of highly active and psychotropic agents
  • use of narcotic agents.
  • the hospital pharmacy is also licensed.

The Hospital is approved for organization of the clinical trials of medicinal agents and of biomedical cell products.

History of Clinical Hospital «NEUROVITA»

The main technologies of our Hospital date back to 1991 when according to the order of the Head of the Military Medical Directorate of the Ministry of Defense a small interdisciplinary team of molecular biologists, geneticists, biophysicists, biochemists and other specialists from different Ministries and institutions under the guidance of Andrey Bryukhovetskiy, the Medical Service Colonel was established. The goal of the group was to study and develop novel methods of treatment for a complicated contingent of the patients with acute and chronic injuries of the central nervous system and locomotor system in battle trauma using human stem cells, bioengineering and tissue engineering of the neural tissue. Further, Dmitriyeva TB, the Minister of Healthcare of Russia as agreed with Prof. Shumakov VI, the member of the Russian Academy of Science (RAS) and the Head of the Research Institute of Transplantology and Artificial Organs, organized the Group of High Medical Technologies in the Institute and expanded the range of eligible patients. At different times the Group was guided by Shumakov VI, the transplantologist, the member of the RAS, Dmitrieva TB, the psychiatrist, the member of the RAS, Yaryghin VN, the neurobiologists, the member of the RAS, Chekonin VP and Sukhikh GT, the immunologists and the members of the RAS, as well as Davydov MI, the oncologist, the member of the RAS. The specialists of the Group of High Medical Technologies conducted one of the first research of the stem cells (SCs) in the animal models of various diseases on the basis of the Institute and Patrice Lumumba University of People Friendship and the results appeared promising.

Thanks to the support and involvement of Dmitrieva TB, the Minister of Healthcare, and Shumakov VI, the head transplantologist of the country, the clinical trials in humans were approved by the Scientific Board of the Research Institute and in 1996 the first surgical neurotransplantation of the SC was performed. Our research team was the first in the world to transplant SCs intrathecally (into the spinal canal) and intraventricularly in combat injury of the brain. We performed over 100 surgeries in tissue engineering of the spinal cord in humans and over 40 000 infusions of the cell products into the spinal canal of the patients with neural trauma.

Innovations Clinical Hospital «NEUROVITA»

For thirty years we have been accumulating and processing the data of fundamental research and evidence about genomics, transcriptomics and proteomic of a hematopoietic stem cell (HSC)and neural stem cell (NSC) of a human. Our working team was lucky to be guided by the top experts: Prof. Mikhail I. Davydov, the oncologist, the member of the Russian Academy of Science (RAS); Prof. Gennadiy T. Sukhikh, the expert in immunology, the member of the RAS; Prof. Vadim P. Chekhonin, the expert in cell therapy, the member of the RAS; Prof. Yaryghin, the expert in neurobiology, the member of the RAS, and Prof. Shumakov, the expert in transplantology, the member of the RAS. These data are published in 15 scientific monographs, 220 publications in the peer reviewed national and international journals and protected by over 35 patents of inventions and applications.

The result is the promising hypothesis that fatal oncological, neurodegenerative and autoimmune diseases of the human civilization as well as aging are not the disorders of the pathospecific (cancer-specific, neurospecific and so on) protein molecules in the differentiated cells of the specialized tissue, but the post-genomic diseases of the hematopoietic stem cells (HSCs), tissue-specific progenitors and stem cells (SCs). This hypothesis provided the foundation for our novel biotechnologies.

The hospital attracted private investment to establish the material basis and initiated a highly technological business in the area of personalized post-genomic and regenerative medicine. We have developed the following innovative biomedical technologies:

  1. artificial neural tissue;
  2. the therapy of organic injuries of the brain and spinal cord with the HSCs;
  3. ultra-early molecular-biological diagnostic of cancer and neurodegenerative diseases by mapping and profiling membrane antigens of the HSCs and HPCs;
  4. precision immunotherapy of cancer;
  5. anti-tumor molecularly-targeted cell products;
  6. remote multi-wave radioneuroengineering of the brain and spinal cord;
  7. anti-tumor artificial cell-pharmaceutical immunity.

A personalized approach is the basis for our novel biomedical platform to treat injuries of the organs and tissues, and especially the neural tissue of the brain and spinal cord. The platform is best illustrated by the patented medical biotechnology Remote-control contactless multi-wave radioneuroengineering of the brain and spinal cord of the human (see details).

The Hospital has developed a novel biomedical platform of the therapy of hereditary diseases of the nervous system (HDNS). We admit the impossibility to currently cure the HDNS as every cell of the patient with HDNS contains the defect but we lay our hopes on the nature-like novel technology of the binary DNA-targeted biotherapy to stabilize the genome. All components of it are approved for clinical use and are able to arrest the progress of the HDNC to prevent relapses and lethal oncological, autoimmune and neurodegenerative complications (see details).

The Hospital has developed a biomedical platform to extend the lifespan of humans and to achieve active longevity. For it, the autologous HSCs are gathered at a young age and the proteomic mapping and profiling of the membrane antigens of HSCs helps detect the main diseases of civilization in them at an early stage before clinical manifestation of the disease. The harvested mononuclear cells of peripheral blood, HSCs and HPCs can be cryopreserved and stored. They avoid the systemic process of aging and thus can be used in elderly age. The technology extends the lifespan in mammals by 28-30%, which is experimentally proven. We are starting the project to gather the HSCs and to further store them in a cryobank (see details).

We also lay hopes on a novel cell product Hemacell that is based on the thawed HSCs in the leukapheresis product of mononuclear cells of peripheral blood that has been incubated with Panagen therapeutic substance. The combination of the cellular-pharmaceutical cell product Hemacell demonstrated the pronounced anti-tumor effect, neuroregenerative potential in the recovery of the brain and spinal cord and rejuvenating effect in a human organism. The technology is protected by the patent for the invention of Russia. The product can be used in the patients with Alzheimer’s disease and other types of dementia. The preclinical trials are completed, the protocols of the clinical trials are ready. The clinical trials of the cell product start after the approval of the Ministry of Healthcare of Russia. In 2021 young scientists of our team headed by Sergey S.Bogachov (Novosibirsk) were awarded with the Award of the Russian Federation President for the therapeutic substance Panagen. The technology of incubation of the non-manipulated cells of bone marrow and HSCs with the approved therapeutic substance Panagen opens a unique opportunity for molecular-biological stabilization of the unstable genome, permitting the opportunity to compensate the clinical condition in the cases of various hereditary, oncological and autoimmune diseases by replacement infusion of molecular-biologically restored HSC and HPCs. Integration of cell and postgenomic technologies without genome editing permits restoration of the hematopoiesis in mammals even after three- or even five-fold increase of the dose of the lethal ionizing radiation of their HSCs. The approach is supposed to be able to arrest proliferation in a cancer stem cell (CSC) in different types of cancer and prevents the fatal aplasia of the bone marrow in chemo- and radiotherapy.

Over 20 years’ experience of chemo-, radio- and palliative therapy in severe cases of cancer, led to the development of the oncoimmunological biomedical platform. Its goal is to increase the survival rates, lifespan of the patients and to improve the efficacy of rehabilitation. We offer solutions to these problems using the technologies of regenerative medicine (see details). All technologies are patented and tested in experimental animals and humans with the help of the leading experts of the Federal Research Centers of the Ministry of Healthcare and Russian Academy of Science. The co-authors of our patents are Sukhikh GT, the member of RAS, Yaryghin VN, the member of RAS, Chekhonin VP, the member of RAS, Davydov MI, the member of RAS and many others.

Our broad experience of using non-manipulated and low manipulated cell products of HSCs proved safe as there have not been a single case of cell therapy induced cancer, disability or death. The effectiveness and safety of the cell product is based on our know-how when the stem cells are expanded and restored without culturing and development of a cell line. We discovered a nature-like mechanism of restoration and compensation of the unstable genome of the cells in certain hereditary neural diseases, autoimmune and neurodegenerative disease; and this mechanism is almost a complete alternative to genome editing. It opens a unique opportunity to develop innovative individually tailored methods of compensation of some of the conditions induced by the incurable disorders.

STRATEGY Clinical Hospital «NEUROVITA»

The recent events in medicine can be named a biotechnological post-genome and regenerative revolution. The healthcare of the world witnesses the biotechnological boom and stands at the threshold of a new era of genome and post-genome molecular-biological (epigenomics, RN-omics, proteomics, transcriptomics, metabolomics, secretomics and so on) human research. Active introduction of the advances of genomics, post-genomics and bio-informatics into the clinical practice has significantly expanded and still keeps expanding our understanding of the pathological processes at the level of molecular and cellular structures of the human organism. The achievements of the genetics and molecular biology permitted the discovery of a great number of the protein, DNA and RNA markers of the pathological processes in the body. This progress offers an opportunity to focus at the pre-clinical stage of the disease, that is, at the earliest stage of the pathology onset when there are no clinical signs of the disease.

Now it is possible to monitor the dynamics of the pathological process by the biological markers of the disease.

The key links of the work with the patients in our Hospital are prediction of the risk of the disease, preclinical diagnostics and detection of the stage of the disease and the earliest of all possible molecularly targeted pharmaceutical interference or use of the technologies of the regenerative (genomic, gene engineering, peptide engineering, cellular engineering tissue engineering and so on) medicine in order to prevent the disease development or its transfer to a more pronounced stage. These principles are the basis for a new strategy of three Ps of contemporary global and national medicine: predictive, preventive and personalized. To date this strategy is a priority both for global and for national medicine and is officially approved by the Order of the Ministry of Healthcare of Russia #186 dated April 24, 2018.

The personalized medicine became our main instrument in the therapy of our complicated patients. According to the definition of the US President's Council of Advisors on Science and Technology the term'Personalized medicine' refers to the tailoring of medical treatment to the individual characteristics of each patient. It does not literally mean the creation of drugs or medical devices that are unique to a patient, but rather the ability to classify individuals into subpopulations that differ in their susceptibility to a particular disease or their response to a specific treatment. Preventive or therapeutic interventions can then be concentrated on those who will benefit, sparing expense and side effects for those who will not’. Horizon 2020, the EU's research and innovation funding program defined personalized medicine as 'a medical model using characterization of individuals’ phenotypes and genotypes (e.g. molecular profiling, medical imaging, lifestyle data) for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention.'

The results of the prediction, prevention and personalization approach to the therapy of our patients can be summed up in several paragraphs. For 20 years of the work of the hospital, the principle of three Ps became essential in the diagnostics and therapy of extremely difficult contingent with neurological diseases, autoimmune, oncological and neurooncological diseases as well as hereditary diseases of nervous system. This innovative methodological individualized approach to every patient of the Hospital provided the efficiency of the personalized therapy in 60.4% of our low curable cases. It became possible thanks to the development of the predictive system of ultra-early diagnostics of some types of cancer, neurogenerative and autoimmune diseases on the basis of the biomarkers of the membrane surface of the hematopoietic stem cell (the method is protected by the patent). The biomarkers permit prognosis of the presence, dynamics and probability of the disease progress at the preclinical stage of the disease using the technologies of artificial intelligence. Detection of the disease by the unique profiles of molecular markers of the HSC at the pre-clinical stage when the standard molecular (cancer-specific, neurospecific an immunospecific) protein and RNA markers are not detectable yet, lets us propose unique medical and biological measures to prevent lethal oncological disorders and some of the neurodegenerative disease (Parkinson’s, Alzheimer’s, Binswanger diseases, amyotrophic lateral sclerosis, systemic cortical atrophy and others) to our patients. Proteomic assay of HSCs and the proteomic profile of the membrane antigen of HSC give us the information about the pathologically specific (cancer-specific, neurospecific, autoimmune) immune insufficiency of an individual and stability of their HSC genome. In case the state of the HSC proteome is compensated and, accordingly, the genome is stable, to prevent the disease we first started using the protocol of the harvest of the patient’s HSCs and their cryopreservation. That is, for the first time we applied molecular proteomic diagnostic knowledge for prediction and prevention of the disease. If the donor develops a disease, the medical-biological insurance is already provided, especially in the cases of familial oncological, neurodegenerative and autoimmune diseases and thus offering an opportunity to arrest the disease progress and survive in the development of the lethal disease due to the transplantation of the autologous HSCs.

We have shown that in the cases of autoimmune disorders, such as multiple sclerosis or systemic lupus erythematosus when the transplantation of the autologous bone marrow effectively arrests the disease development, the proteomics of the patient’s HSCs must be studied before the transplantation. It appears that only if the HSC is healthy, the efficiency of the bone marrow transplantation can be guaranteed in 95%, in all other cases the disease relapses.

The personalized approach that we have developed is based on the biotechnologies of the regenerative and post-genomic medicine. Just as in the hospitals of the EU and USA, we use patients’ own (autologous) non-manipulated and/or minimally manipulated cell products according to the mechanism of “exclusion for hospital production” considered the medical technology. These products are routinely manufactured in our hospital in Russia according to the individual quality standards by the personal prescription for one specific patient. The Hospital has a practical experience of the development and clinical use of these technologies in over 9000 patients from 50 countries of the world. This work led to 202 publications in national and international peer-reviewed journals, 13 monographs, three of which are published in the USA and Sweden in English, 7 chapters in the multi-authored monographs; ten technologies have been patented in 35 patents of the Russian Federation and one US patent.

To date, 19800 patients have been treated in the Hospital, 12500 of them received our highly technological therapy. The key fields of the hospital activity are personalized neurology, neurosurgery, oncology, preventive neurooncology and oncoimmunology, regenerative and post-genome medicine and hereditary diseases of the nervous system.

Over 4000 intrathecal, intra-ventricular and intra-arterial transfusions of the cell preparations and products, 105 highly technological surgeries on tissue-engineering of the spinal cord in humans. The Hospital is a world leader in the remote-controlled contactless multi-wave radioneuroengineering. The innovative remote-controlled approach to the restoration of the brain and spinal cord was patented and awarded by the Rospatent as one of the top hundred best inventions in Russia in 2017.

Отзывы пациентов



  • КЛИНИЧЕСКИЙ ГОСПИТАЛЬ «НЕЙРОВИТА»
  • КЛИНИЧЕСКИЙ ГОСПИТАЛЬ «НЕЙРОВИТА»
  • КЛИНИЧЕСКИЙ ГОСПИТАЛЬ «НЕЙРОВИТА»

Новости

 

Книга "Нейроинженерия и нейротехнологий"

Книга "Нейроинженерия и нейротехнологии" - Москва: Издательские решения, 2021. - 424с Уважаемые...

Подробней

Торжественное открытие нового здания госпиталя

Торжественное открытие нового здания госпиталя 12 мая 2022 года в торжественной обстановке...

Подробней

Проконсультироваться со специалистом

Обратная связь

Ваше сообщение было успешно отправлено